

August 14, 2019

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir,

Subject: Outcome of Board Meeting.

This has reference to our letter dated 07th August 2019.

At the meeting of the Board of Directors of the company held on 14th August 2019 the following decisions were taken:

We are enclosing here to the unaudited quarterly results for the quarter ended 30th June 2019.

This is for your information and records.

Thanking you

Yours Sincerely

For TRANSGENE BIOTEK LIMITED



DR K KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Encls : as above



TRANSGENE BIOTEK LIMITED

68, 69 & 70, Anrich Industrial Area, Bolarum, Medak District - 503325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Amount in Rs.)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---------|--|---------------------------|---------------------------------------|---------------------------|-------------------------|
| | | 30.06.2019 (Unaudited) | 31.03.2019 (Audited) (Ref Note.10) | 30.06.2018 (UnAudited) | 31.03.2019 (Audited) |
| 1 | Revenue from operations | - | - | 7,12,870 | 7,12,870 |
| 2 | Other income (net) | 4,38,470 | 1,90,62,368 | 4,38,470 | 2,03,77,778 |
| 3 | Total income (1 + 2) | 4,38,470 | 1,90,62,368 | 11,51,340 | 2,10,90,648 |
| 4 | EXPENSES | | | | |
| | Cost of materials consumed | 4,01,539 | 1,95,879 | (1,476) | 3,38,525 |
| | Purchase of Stock-in-trade | - | - | - | - |
| | Changes in inventories of finished goods, work-in-progress and Stock-in-trade | - | - | - | - |
| | Employee benefits expense | 7,58,938 | 8,05,402 | 4,60,811 | 24,81,867 |
| | Finance costs | 15,50,792 | 6,26,374 | - | 25,05,496 |
| | Depreciation and amortisation expense | 2,47,42,286 | 2,47,55,236 | 2,47,23,250 | 9,89,42,929 |
| | Other expenses | 7,98,039 | 19,93,727 | 8,49,056 | 47,48,967 |
| | Total expenses | 2,82,51,554 | 2,83,76,618 | 2,60,31,641 | 10,90,17,784 |
| 5 | Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 6 | Exceptional item (net) | - | - | - | - |
| 7 | Profit before tax (5 - 6) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 8 | Tax expense | | | | |
| | Tax adjustments for earlier years | - | - | - | - |
| | Current tax | - | - | - | - |
| | Deferred tax | - | - | - | - |
| | Total tax expense | - | - | - | - |
| 9 | Profit for the year (7 - 8) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 10 | Other comprehensive income | | | | |
| | A Items that will not be reclassified subsequently to profit or loss | | | | |
| | (a) Remeasurements cost of post employment benefits | - | (5,305) | 262 | (5,005) |
| | Total other comprehensive income | - | (5,305) | 262 | (5,005) |
| 11 | Total comprehensive income for the year (9 + 10) | (2,78,13,094) | (93,19,555) | (2,48,80,039) | (8,79,32,141) |
| 12 | Earnings per equity share | | | | |
| | (Equity shares, par value of Rs. 10 each) | | | | |
| | Basic (Rs.) | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 |
| | Diluted (Rs.) | (0.37) | (0.12) | (0.33) | (1.16) |
| | | (0.37) | (0.12) | (0.33) | (1.16) |

1) As required under clause 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Statutory Auditors have conducted a limited review of the above financial results for the quarter ended 30th June 2019.

2) The Consolidated un-audited financial results for the quarter ended June 30, 2019 were reviewed by the Audit Committee and approved by the Board of Directors Of Transgene Biotech limited at the Meeting held on 14th August 2019

3) The Company is operating in only one segment of Bulk Drugs, hence Segment Wise Report is not applicable as per IND AS 108.

4) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable

5) The Standalone financial results for the quarter ended June 30, 2019 comprise results of Transgene Biotech Limited.

6) As reported in the earlier quarter, discussions with different parties for a strategic partnership for oral delivery of their chosen molecules using TrabiORAL platform technology are ongoing.

7) The legal process for recovery of GDR funds is progressing as reported earlier.


8) Adjudication notice from SEBI was received but has been requested for postponement due to serious health reasons of two of the Directors mentioned in the said notice. We are waiting for the next date of hearing.

9) No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

10) The figures for the three months ended March 31, 2019 are arrived at as difference between audited figures in respect of full financial year and the unaudited published months of the relevant financial year. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.

Place : Hyderabad
Date: 14 August 2019


Chairman and Managing Director





TRANSGENE BIOTEK LIMITED

68, 69 & 70, Anrich Industrial Area, Bollaram, Medak District - 503325, Telangana

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019

(Amount in Rs.)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---------|---|---------------------------|---------------------------------------|---------------------------|-------------------------|
| | | 30.06.2019 (Unaudited) | 31.03.2019 (Audited) (Ref Note.10) | 30.06.2018 (UnAudited) | 31.03.2019 (Audited) |
| 1 | Revenue from operations | - | - | 7,12,870 | 7,12,870 |
| 2 | Other income (net) | 4,38,470 | 1,90,62,368 | 4,38,470 | 2,03,77,778 |
| 3 | Total income (1 + 2) | 4,38,470 | 1,90,62,368 | 11,51,340 | 2,10,90,648 |
| 4 | EXPENSES | | | | |
| | Cost of materials consumed | 4,01,509 | 1,95,879 | (1,476) | 3,38,525 |
| | Purchase of Stock-in-trade | - | - | - | - |
| | Changes in inventories of finished goods, work-in-progress and Stock-in-trade | - | - | - | - |
| | Employee benefits expense | 7,58,938 | 8,05,402 | 4,60,811 | 24,81,867 |
| | Finance costs | 15,50,792 | 6,26,374 | - | 25,05,496 |
| | Depreciation and amortisation expense | 2,47,42,286 | 2,47,55,236 | 2,47,23,250 | 9,89,42,929 |
| | Other expenses | 7,98,039 | 19,93,727 | 8,49,056 | 47,48,967 |
| | Total expenses | 2,32,51,564 | 2,83,76,618 | 2,60,31,641 | 10,90,17,784 |
| 5 | Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 6 | Exceptional item (net) | - | - | - | - |
| 7 | Profit before tax (5 - 6) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 8 | Tax expense | | | | |
| | Tax adjustments for earlier years | - | - | - | - |
| | Current tax | - | - | - | - |
| | Deferred tax | - | - | - | - |
| | Total tax expense | - | - | - | - |
| 9 | Profit for the year (7 - 8) | (2,78,13,094) | (93,14,250) | (2,48,80,301) | (8,79,27,136) |
| 10 | Other comprehensive income | | | | |
| | A Items that will not be reclassified subsequently to profit or loss | | | | |
| | (a) Remeasurements cost of post employment benefits | - | (5,305) | 262 | (5,005) |
| | Total other comprehensive income | - | (5,305) | 262 | (5,005) |
| 11 | Total comprehensive income for the year (9 + 10) | (2,78,13,094) | (93,19,555) | (2,48,80,039) | (8,79,32,141) |
| 12 | Earnings per equity share | | | | |
| | (Equity shares, par value of Rs. 10 each) | | | | |
| | Basic (Rs.) | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 | 7,57,70,000 |
| | Diluted (Rs.) | (0.37) | (0.12) | (0.33) | (1.16) |
| | | (0.37) | (0.12) | (0.33) | (1.16) |

1) As required under clause 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Statutory Auditors have conducted a limited review of the above financial results for the quarter ended 30th June 2019.

2) The Consolidated un-audited financial results for the quarter ended June 30, 2019 were reviewed by the Audit Committee and approved by the Board of Directors Of Transgene Biotech limited at the Meeting held on 14th August 2019.

3) The Company is operating in only one segment of Bulk Drugs, hence Segment Wise Report is not applicable as per IND AS 108.

4) This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable

5) The Consolidated financial results for the quarter ended June 30, 2019 comprise results of Transgene Biotech Limited, its subsidiary in HK.

6) As reported in the earlier quarter, discussions with different parties for a strategic partnership for oral delivery of their chosen molecules using TrabiORAL platform technology are ongoing.

7) The legal process for recovery of GDR funds is progressing as reported earlier.

8) Adjudication notice from SEBI was received but has been requested for postponement due to serious health reasons of two of the Directors mentioned in the said notice. We are waiting for the next date of hearing.

9) No. of Investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

10) The figures for the three months ended March 31, 2019 are arrived at as difference between audited figures in respect of full financial year and the unaudited published months of the relevant financial year. Also the figures upto the end of third quarter had only been reviewed and not subjected to audit.

Date: 14 August 2019



For and on behalf of Board of Directors

[Signature]

Chairman and Managing Director



Limited Review Report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 June 2019 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.


4. The Statement includes the results of the following entities

Name of the entity

Relationship


1. Transgene Biotek HK Limited


Subsidiary



5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of one subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2019, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S


Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date: 14/08/2019



Unique Document Identification Number (UDIN) for this document is
19212664AAAAAU7824




Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Tansgene Biotek Limited for the quarter ended 30 June 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S

Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad



Date: 14/08/2019